Lilly asks to join lawsuit over compounded versions of its weight-loss drugs [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply. In a motion filed in Fort Worth, Texas federal court late on Wednesday, Lilly said it could not rely on the FDA to fully defend its interests in the case, which will determine whether compounding pharmacies and facilities can keep selling cheaper versions of the company's weight-loss drug Zepbound and diabetes medicine Mounjaro, which have the same active ingredient, tirzepatide. The FDA declined to comment. The Outsourcing Facilities Association, which brought the lawsuit along with a Texas compounding pharmacy did not immediately respond to requests for comment. The compounded drugs at issue, which are essentially copies of the branded prescription medicines but not approved by the FDA, can only be made in significant amounts if there is a shortage. The FDA decided in October that there was no longer a shortage of the tirzepatide drug
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk seeks to block compounded Victoza [Seeking Alpha]Seeking Alpha
- Could Trump Make A Big Weight Loss Drug Deal? [Forbes]Forbes
- GLP-1 questions emerge for 2025 [Yahoo! Finance Canada]Yahoo! Finance Canada
- GLP-1 questions emerge for 2025 [Yahoo! Finance]Yahoo! Finance
- Why Novo Nordisk (NVO) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website